الفهرس Only 14 pages are availabe for public view
 |  | from | 237 |  |  |
| | | from | 237 | | |
Abstract
Despite the standard treatment for advanced NSCLC, the overall prognosis is very poor. Using molecular markers as a predictor for chemotherapy response is an important area of research. from Jan 2011 to Jan 2014, we conducted a prospective study on 85 chemotherapy naive patients with advanced stage NSCLC. ERCC1, BRCA1 and RRM1 proteins level in blood samples by ELISA and mRNA expression in paraffin embedded tumor tissues were detected. All patients received gemcitabine and cisplatin. Assessment of molecular expression, correlation with response, TTP and OS were done. 71patients were evaluable for response. 43.3% of patients with high ERCC1 mRNA expression were non responders (PD); in contrary 73.2 % of ERCC1 negative patients had clinical benefit (PR or SD). Patients with high ERCC1 expression had shorter TTP (P = 0.001) and OS (P = 0.022), Patients with low RRM1 expression had longer OS (P = 0.052). No correlation between the BRCA1 expression and both the response and survival were found.